Hey - do I detect the same sardonic style as our old friend David S. (from the AGPH and CNTO threads)? Maybe you are just playmates and it rubbed off.
As to the issue of retreatment after Bexxar, the following extract from a CLTR release seems to answer your concerns:
Dr. Valente also reported that subsequent therapies have been administered following Bexxar treatment and that generally neither the low blood counts nor HAMA positive readings associated with Bexxar precluded patients from receiving other therapies. Of the 432 patients, 183 had progressed following Bexxar treatment at the time of this analysis. One-hundred-fifty-six (156) of the 183 patients who progressed received a total of 280 subsequent therapies, including re-treatment with Bexxar, single agent or combination chemotherapy, radiation therapy, Rituximab, bone marrow or stem cell transplant, biological therapy, and/or steroid therapy. The majority of patients (101 patients or 65 percent) went on to receive chemotherapy following Bexxar. The chemotherapy regimens included combination and salvage therapies such as ESHAP, DHAP, and FND. Twenty patients (13 percent) were re-treated with Bexxar. Fifteen patients (10 percent) underwent stem cell or bone marrow transplants. Forty-one patients (25 percent), six of whom were known to be HAMA positive, received Rituximab as a subsequent therapy. There was no correlation between HAMA positivity and either infusion reaction or response to Rituximab. Twenty-five of the 183 patients were not treated with subsequent therapy primarily due to slowly progressive disease not requiring therapy. Only one patient did not receive subsequent therapy due to low blood counts.
Peter |
